ESTRO 35 2016 S967 ________________________________________________________________________________ timing of surgery and the RT schedule could influence tumor dissemination and subsequently patient overall survival. We demonstrated the impact of NeoRT on metastatic spreading in a Scid mice model. After an irradiation of 2x5gy, we show more metastasis in the lung when the mice are operated at day 4 compared to day 11 (1). Here, our aim is to evaluate with functional MRI (fMRI) the impact of the radiation treatment on the tumor microenvironment and subsequently to identify non-invasive markers helping to determine the best timing to perform surgery for avoiding tumor spreading.
: Graphs representing F factor in tumor bearing mice before and after radiotherapy in MDA-MB 231(n= 6) (Scid model) and in 4T1 (n=4) (BalbC model); (*=p<0, 05) Conclusion: For the first time, we demonstrate the feasibility of repetitive fMRI imaging in mice models after NeoRT. With these models, we show a significant difference between the pre-irradiated acquisition and day 6 or day 3 for perfusion F. This change occurs between the two previous time points of surgery demonstrating a difference in the metastatic spreading (1). These results are very promising for identifying noninvasive markers for guiding the best timing for surgery. Reference: (1) The timing of surgery after neoadjuvant radiotherapy influences tumor dissemination in a preclinical model Natacha Leroi et al. (2015) Oncotarget vol. 5 
EP-2050 The assessment of fractal dimension with Dual Energy CT gives information on lung cancer biomarkers

Material and Methods:
A retrospective review (May 2013 -January 2015) of 125 lung cancer patients with lung GSI (Gemstone Spectral Imaging) and perfusion CT imaging on a DECT was fulfilled. For 25 of them, the fraction of Ki-67 positive-tumour cells was analysed and for 19 patients KRASpositive (mutation detected) or KRAS-negative (mutation not detected) character was evaluated (11 positive, 8 negative). DECT examination was performed on a Discovery CT 750 HD scanner (GE Healthcare, USA). For the perfusion exam, blood volume, blood flow and permeability-surface studies were analyzed. At GSI exam, images related to absorption in Hounsfield units (HU), iodine concentration and monochromatic virtual images reconstructed at 40, 60, 80, 100, 120 and 140 keV were assessed. Tumour fractal dimension was measured with the use of Mapfractalcount plug-in for ImageJ (National Institute of Health, USA) software. After extraction of DNA from paraffin embedded tissue using QIAamp DNA Investigator Kit (Qiagen), analysis of the KRAS gene exons 2 (codons 12/13) and 3 (codon 61) were performed in order to identify possible associated mutations with real-time PCR kit cOBAS® KRAS Mutation Test (Roche Diagnostics, SL). T-Student test or U Mann-Whitney test were used to compare differences between KRAS-positive from KRAS-negative cohorts. Pearson correlation coefficient was used to study linear relationship between fractal dimension and the fraction of Ki-67 positive-tumour cells.
Results: Best result (p= 0.02) for distinguishing KRAS-positive cohort was obtained for lesion fractal dimension at 140 keV virtual image. This parameter showed an AUC= 0.80. It was predictive of KRAS-positive with 90.9% sensitivity and 75.0% specificity for a fractal dimension threshold of 2.352. There was a correlation of lesion fractal dimension in blood volume image and the fraction of Ki-67 positive-tumour cells (p= 0.04).
Conclusion:
Ki-67 positive-tumour cells and KRAS-positive biomarkers lead to tumour heterogeneity that modify radiographic image. Fractal dimension parameter quantifies such imaging heterogeneity and could allow to differentiate them. A higher fractal dimension (higher heterogeneity) of lesion at virtual monochromatic images is measured for KRAS-positive mutation, while a higher fraction of Ki-67 positive-tumour cells is associated with a more homogeneous blood volume at perfusion.
EP-2051
Hsp70 as a tumor specific biomarker in primary glioblastoma multiforme patients F. Laemmer 1 S968 ESTRO 35 2016 _____________________________________________________________________________________________________ Purpose or Objective: The standard treatment regimen of patients with primary glioblastoma multiforme (PGBM) consists of neurosurgery, radio-and chemotherapy. Despite this multimodal treatment the overall survival of patients with PGBM is still approximately 15 months. The stress-inducible heat shock protein 70 (Hsp70) contributes to tumor cell survival and is associated with poor prognosis, metastasis and therapy resistance. Therefore, the aim of this study is to analyze Hsp70 in PGBM tumor samples as a future prognostic biomarker and possible therapy target.
Material and Methods:
Formalin fixed paraffin embedded (FFPE) sections of 44 human PGBM patients (isocitrate dehydrogenase wildtype) were analyzed by immunohistochemistry for Hsp70 (cmHsp70.1, IgG1, multimmune GmbH, Munich, Germany). Taking the intensity of Hsp70 staining into account, quantitative expression analysis of tumor cells with stained cytoplasm was performed. Two categories of Hsp70 staining were defined: Up to 40% and more than 40% positive tumor cells within the tumor regions. The Hsp70 immunoreactivity was correlated with the survival of the patients using the Cox regression analysis.
Results: Preliminary data show that the median survival of PGBM patients can be predicted by the Hsp70 immunoreactivity of the tumor cells. Regression analysis showed that patients with Hsp70 expression of more than 40% have a higher risk of disease progression with a hazard ratio of 2.59 (p= 0.045).
Hsp70 expression in FFPE IHC section (Hsp70 positive tumor cells are brown)
Conclusion: These data provide the first evidence that Hsp70 expression in FFPE sections of PGBM patients is associated with disease progression. Moreover, measuring Hsp70 in FFPE sections of PGBM patients before radiotherapy treatment may be used as biomarker for the success of the therapy. The independency of Hsp70 expression and O6-methylguanin-DNA methyltransferase (MGMT) is currently under investigation. Purpose or Objective: In recent years, it has been suggested that wound drainage fluids (WDF) of patients operated for head and neck squamous cell carcinoma (HNSCC) may be characterized by molecular biomarkers with potential prognostic and predictive value. The detection of adverse features in the early perioperative setting could possibly lead to a refinement of current adjuvant treatments in high-risk patients. The purpose of our study is to report on the feasibility and preliminary results of a pilot prospective study on WDF analysis in HNSCC.
EP-2052 Expression of molecular biomarkers in wound drainage
